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Abstract
Background: Traditional peripheral biofeedback has grade A evidence for effectively treating migraines. Two
newer forms of neurobiofeedback, EEG biofeedback and hemoencephalography biofeedback were combined with
thermal handwarming biofeedback to treat 37 migraineurs in a clinical outpatient setting.
Methods: 37 migraine patients underwent an average of 40 neurofeedback sessions combined with thermal
biofeedback in an outpatient biofeedback clinic. All patients were on at least one type of medication for migraine;
preventive, abortive or rescue. Patients kept daily headache diaries a minimum of two weeks prior to treatment
and throughout treatment showing symptom frequency, severity, duration and medications used. Treatments were
conducted an average of three times weekly over an average span of 6 months. Headache diaries were examined
after treatment and a formal interview was conducted. After an average of 14.5 months following treatment, a
formal interview was conducted in order to ascertain duration of treatment effects.
Results: Of the 37 migraine patients treated, 26 patients or 70% experienced at least a 50% reduction in the
frequency of their headaches which was sustained on average 14.5 months after treatments were discontinued.
Conclusions: All combined neuro and biofeedback interventions were effective in reducing the frequency of
migraines with clients using medication resulting in a more favorable outcome (70% experiencing at least a 50%
reduction in headaches) than just medications alone (50% experience a 50% reduction) and that the effect size of
our study involving three different types of biofeedback for migraine (1.09) was more robust than effect size of
combined studies on thermal biofeedback alone for migraine (.5). These non-invasive interventions may show
promise for treating treatment-refractory migraine and for preventing the progression from episodic to chronic
migraine.
Background
Migraine is a common, disabling and often progressive
disorder characterized by increased excitability of the
central nervous system [1,2]. It occurs in 18% of women
and 6% of men in the US with peak prevalence in indi-
viduals between the ages of 25 and 55 [3]. Economic
burden of migraine in the US is estimated to be
approximately 13 billion annually [4]. Biofeedback is a
common intervention in pain management. For
migraine treatment, the most frequently used biofeed-
back methods have been peripheral skin temperature
biofeedback, blood- volume-pulse and electromyography
feedback [5]. In a recent meta-analysis involving bio-
feedback for the treatment of migraine, Grade A
evidence [6] was found for the efficacy of the above
methods which proved stable over a 17 month follow-
up phase [5]. Numerous studies explore peripheral bio-
feedback [5] but scant studies exist on using neurofeed-
back methods to treat migraine [7-11]. Although this
study looks at neurofeedback, it is not the sole interven-
tion. Instead of providing only neurofeedback protocols
as the sole modality in this clinical setting, the lead
author, who is a clinician in private practice, decided
early on to utilize evidence-based thermal biofeedback
methods in addition to the neurofeedback in order to
maximize the patient’s chances of success.
Neurotherapy is a broad term referring to the many
types of biofeedback used to deliver information about
the central nervous system which involve blood flow,
thermal output from the brain or electrical activity.
Neurofeedback (also called neurobiofeedback or EEG
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back that uses an EEG to give clients information about
their brainwaves and gradually and subtly teaches people
how to alter their brainwave activity. Sensors are
attached to the scalp and the raw EEG signal is ampli-
fied, the frequency spectrum is extracted via a Fourier
transform and selected frequency components are dis-
played through a user interface such as a video game.
Unlike peripheral biofeedback that monitors the status
of peripheral aspects of the sympathetic and parasympa-
thetic nervous systems (e.g. respiration, galvanic skin
response), neurofeedback monitors central nervous sys-
tem activity.
A preliminary review of the literature on the clinical
applications of neurofeedback suggests that it may be
effective for a number of cognitive, emotional, and phy-
sical problems [12-15]. The neurofeedback literature is
still in its infancy, and with the exception of ADHD,
there are few double-blind, placebo-controlled studies.
Although there are randomized controlled studies of
neurofeedback applied to conditions such as ADD/
ADHD, uncontrolled epilepsy, learning disabilities, anxi-
ety, post traumatic stress disorder, alcoholism, autism
and traumatic brain injury [15], there are many areas of
application including migraine where controlled studies
using neurofeedback do not yet exist. Nevertheless, the
body of research is growing, and the practice-based stu-
dies that form the basis of much of the published litera-
ture are stimulating a great deal of interest in the field.
Abnormalities in electrophysiological activity have
commonly been found in the brains of migraine patients
[16-21], therefore it is plausible that interventions invol-
ving the EEG might be of benefit [16]. Children afflicted
with migraine, those with and without aura, demon-
strate increased theta frequencies compared to normal
controls [17]. One popular neurofeedback protocol for
migraine emphasizes protocols rewarding 12-15 HZ at
the temporal lobes at sites T3 and T4 [22]. Siniatchkin
and colleagues demonstrated a significant reduction in
migraines in 10 young migraineurs after 10 sessions of
neurofeedback at midline frontal and central areas
teaching them to control slow cortical potential activity
representing cortical sensitivity and reactivity [7].
Michael Tansey enabled four migraineurs to eliminate
their migraines after neurofeedback training along mid-
line frontal and central areas which showed that low fre-
quencies became less dominant and higher frequencies
were augmented [8]. An older study found that thermal
biofeedback was no more effective than EEG alpha bio-
feedback and self hypnosis in treating migraine [9].
Neurofeedback training also includes a newer method
called hemoencephalography, which targets the frontal
lobe [23]. Passive infrared hemoencephalography (pIR
HEG) is a form of biofeedback for the brain that
measures and feeds back information on the thermal
output of the frontal lobe [10,23]. Unlike electromyo-
graphic (EMG) feedback which involves lowering the
tension of the frontalis or trapezius muscles, pIR HEG
involves increasing the forehead temperature by watch-
ing a movie for feedback. The movie is in operation
when the measured forehead temperature rises and the
movie stops when the temperature drops. The therapist
will increase the threshold as the client learns how to
raise their forehead temperature. Clients are instructed
to calmly concentrate on making the movie continue to
play. Increases in the pIR HEG signal reflect a compo-
site of thermal activity generated by vascular supply,
vascular return and brain cell activity. 100 International
Headache Society (IHS)-diagnosed migraineurs reduced
the frequency of their headaches using this form of bio-
feedback [10,24,25].
Methods
This is a single group outcome, open label study in a
clinical setting where both the patients and those
administering treatment were aware of the treatment
being given. Patients were given Informed Consent for
biofeedback methods administered as well as Informed
Consent to Research as put forth by the lead author’s
ethics committee of the American Psychological Asso-
ciation and the Association of Applied Psychophysiology
and Biofeedback. All signed copies remain on file at The
Better Brain Center. The authors had full access to all
the data in the study and take responsibility for the
integrity of the data and the accuracy of the data
analysis.
Participants
Patients were recruited from the neurofeedback clinic of
the Better Brain Center (formerly called Neurofeedback
Consultants) where most were referred by their primary
care physician or neurologist. Others responded to local
media events covering their neurofeedback work in
treating migraines. 74 headache clients presented to the
clinic between 2004 and 2007. Selection criteria required
that the client have migraine with or without aura and
that this diagnosis be confirmed according to the IHS
classification criteria for headache disorders [24,25].
Patients who had less than one migraine per month or
more than 20 per month were excluded from the study.
This broad range of 1 to 20 migraines per month was
used to keep as many patients as possible in the sample;
however, we also conducted analyses using just the sub-
set of patients with 2 to 14 migraines per month, the
more typical headache frequency criterion used in
migraine studies. The total sample included 37 migraine
patients (29 females and 8 males). Ages ranged from 9
to 79, with the majority (56%) between the ages of 16
and 52, and the remainder evenly split between the
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older group (22% were between 55 and 79). In terms of
medical history, most patients had long, stable histories
of migraine and had tried multiple pharmaceutical treat-
ments prior to neurotherapy. All were having at least
one migraine per month and taking at least one type of
medication (preventive, abortive or rescue) for their
migraines and were not required to discontinue these
during the study (See Table 1). About one-third of the
patients had migraine with aura, and about three-fourths
reported experiencing other kinds of headaches or one
or more other significant conditions (e.g., anxiety,
depression, problems with sleep or focus). All received a
diagnosis of migraine or mixed migraine with tension
type headache. Patients were screened for medication
o v e r u s eh e a d a c h ea n dt h o s et a k i n ga b o r t i v eo rr e s c u e
medications more than 2 or 3 times a week were
referred to their prescribing physician for instructions
on tapering down and possible alternatives to these
types of medications.
Initial assessments
A personal and family headache history was taken at
initial evaluation and a diagnostic interview was per-
formed by a licensed psychologist to confirm the IHS-
diagnosis of migraine with or without aura and to assess
other symptoms and conditions. All patients had also
received a diagnosis of migraine by a physician (neurolo-
gist, family practitioner or OB GYN) prior to entering
this study. For patients who did not have at least two
weeks of headache diaries, they were asked to wait two
weeks to begin treatment in order to keep a baseline
daily diary to record headache frequency and severity.
At the first session and every 10 sessions thereafter, cli-
ents were asked to complete a non-standardized check-
list to indicate changes in headaches as well as other
symptoms (e.g., anxiety, insomnia, other pain types,
depression, and behavioral problems). These checklists,
daily headache diaries and clinical interviews were used
throughout treatment to help determine most effective
protocols and placements which were modified
accordingly.
Follow up data collection
The data reported in this study were collected 3 months
to 2 years after patients stopped coming to the neu-
rotherapy center, either because they had completed the
recommended number of treatment sessions or because
they discontinued treatment on their own. The data
were collected through follow-up telephone surveys con-
ducted by a research consulting firm not affiliated with
The Better Brain Center. Interviewers introduced them-
selves and indicated that they were conducting a follow-
up assessment of The Better Brain Center’s migraine
patients for research purposes, and asked for permission
to continue. Prior to starting treatment patients had
been informed that their data may be used in a future
retrospective study and that they might be interviewed
for a study and all had agreed in writing. The telephone
surveys were conducted during the last half of 2007
using a standardized protocol and prepared list of ques-
tions. The large majority of patients had completed
treatment at least 6 months prior to the follow-up call,
some as long as two years earlier. When asked about
their post-treatment migraine history, participants were
instructed to think about the 6 months immediately pre-
ceding the follow-up interview (not the entire time since
their last treatment) and to estimate, on average, how
many migraines they experienced per month. We
included a broad range of months instead of just the 1
or 2 preceding months for two reasons. First, many
patients experienced fewer than 1 per month post-treat-
ment and a six month period is more likely to capture
the fact that they are not completely migraine free. Sec-
ond, many patients in this sample experienced fluctua-
tions in the number of migraines they experienced per
month, and capturing data for only 1 or 2 months could
misrepresent their typical or average migraine frequency
(although this is not a problem in large samples where
unusually high or low frequency months should be ran-
domly distributed across the sample; in smaller samples
this is less likely to occur and short data collection peri-
ods can be an unnecessary source of error). Pre treat-
ment headache frequency data was provided by
headache diaries kept prior to treatment. Pretreatment
headache frequency was also confirmed by interviews
during follow up data collection. When asked about
Table 1 Number of patients on each type of migraine
medication
Preventives Preventives (off label) Abortives Rescue
Topamax- 5 Skelaxin- 1 Frova - 3 Alleve- 2
Depakote- 4 Requip- 2 Zomig- 2 Tylenol- 7
Inderal- 1 Cymbalta-3 Imitrex- 4 Phenergan-1
Adderal- 3 Relpax- 3 Vicodin- 1
Neurontin- 3 Maxalt- 1 Vicophren-1
Lexapro- 2 Midrin- 1 Advil- 6
Elavil- 1 Migrainol- 1 Fioricet- 4
Botox- 1 Excedrin- 1
Effexor- 4 Toradol- 1
Verapamil- 1 Compazine-1
Prednisone- 2 Butorphenol- 1
Phenobarbitol- 1
Tegretol- 1
Atenolol- 1
Claritin- 1
Vasotec- 1
Tenex- 1
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were also asked to recall the average number of
migraines per month they were experiencing in the 6
months prior to seeking treatment. Interviewers had
access to the migraine frequency data reported at the
initial diagnostic evaluation, and if there were large dis-
crepancies asked for clarification. Large discrepancies
were rare, and were usually the result of misunderstand-
ing the question or mixing headache types. In the 3
cases where participants could not be contacted or
chose not to complete the telephone interview, migraine
frequency data from patient records was used instead of
the telephone survey data. In addition to the migraine
frequency questions, we presented each respondent with
a list of symptoms that are common among clients seek-
ing neurotherapy (e.g., anxiety, focus or attention,
depression, other (non-migraine) headaches, and asked
which they had also experienced prior to treatment. For
each symptom they reported having experienced we
asked them to rate the level of improvement they
experienced with treatment. The options for the 5 point
rating scale included: 0 - No (0%) improvement, 1 Slight
(10-30%) improvement, 2-Moderate (40-60%) improve-
ment, 3-Major (70-90%) improvement, 4- Total (90-
100%) improvement. We also asked all participants to
use the same scale to rate the improvement they felt
they had experienced in their migraines.
Treatment protocol
The study involved treatment using EEG biofeedback,
pIR HEG biofeedback and handwarming biofeedback for
an average total of 40 sessions. Average length of time
in treatment was 6 months. Subjects underwent an aver-
age of 30 frequency-based neurofeedback sessions and
10 pIR HEG sessions for 30 minutes at least twice
weekly. Eleven patients had an interruption in their
treatment after the initial 20 sessions of up to several
weeks but returned for their remaining sessions.
Assessment: A neurophysiological assessment using
EEG measurements was administered using two chan-
nels of the EEG amplifier/software Brainmaster Atlantis
version 3.5 or Brainmaster version 2.5. EEG Data was
collected in three minute segments, 2 channels at a
time. Data was collected under eyes open, eyes closed
and eyes open task conditions at each site. Ten sites
were collected: frontal (F3, FZ, F4), temporal T3, T4)
central (C3, CZ and C4) and parietal areas (P3, P4)
using the International 10-20 system of electrode
placement.
Data collected was used to determine peak amplitudes
for specific frequencies within the 1-38 HZ range. Data
collection was performed at each site with the ground at
FZ and with ipsilateral references and with the ground
at C3 when sampling the FZ site. Sampling rate was 256
samples per second using a third order filter and a 60
HZ notch filter. Amplitude measures were peak to peak
magnitude.
Treatment: The EEG measures were used to guide
neurofeedback training protocols by targeting frequency
ranges with the highest amplitude. All migraine patients
were trained to reduce the amplitude of the targeted fre-
quencies. The EEG training primarily occurred at 5 sets
of homologous sites - (T3-T4, C3-C4, F3-F4, FP1-FP2
and P3-P4). These homologous sites were chosen
according to the lead author’s training in neurofeedback
in which years of clinical experience in treating
migraines by other experienced clinicians is taught [22].
Electrode placements at homologous sites were used
and training always began as a single channel placement
using the first site as the signal and the second site as
reference (example: T3-T4).
When training each site, each client received positive
feedback (visual and auditory rewards via a video type of
game) whenever EEG activity exceeded certain ampli-
tude thresholds within a target band (called the reward
band). Training each homologous site rewards the dif-
ference between the amplitude at each site of the target
frequency. Simultaneously, clients received no feedback
whenever excessive high amplitude activity occurred in
certain frequency bands (called the inhibit band) that
had been identified during the assessment. This lack of
auditory reward (no beep or feedback) is designed to
discourage the client from making excessive activity in
the inhibit band whenever this activity exceeds the set
threshold.
These protocols also reflect findings of EEG abnorm-
alities commonly found in migraine patients [7,16-20].
The reward and inhibit frequencies chosen for each site
were also selected according to the individual’sn e u r o -
physiological assessment and they were also based on a
history of training recommendations considered to be
optimal for migraine stabilization by the authors and
other practitioners in the field [22]. For example, for
temporal lobe sites we rewarded a target range of 12-15
HZ. Lower target range rewards were selected at poster-
ior and frontal regions. During training, sometimes
reward frequencies were lowered by 2 HZ from the
starting point. For T3-T4, for example, after starting at
12-15 HZ, we may move down to 10-13 HZ. Small
changes in the targeted reward frequency can produce
noticeable clinical improvement, readily identified by the
migraine sufferer. For the migraine population, however,
we have observed that lowering the target frequency
further than 2 HZ frequently can have a destabilizing
effect and may actually trigger a migraine.
Training Objectives: Patients were told simply to
“make beeps” or an auditory reward which occurs when
they achieve the training objectives of increasing the
reward amplitude and reducing excessive amplitude in
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w e r ei n h i b i t e da ta l lt h es i t e sr a n g e db e t w e e n2a n d1 4
HZ (low inhibit) and between 15 and 38 HZ (high inhi-
bit). The reward frequency range across all the sites was
usually between 8-18 HZ, with a 3 HZ band width. Each
set of sites had their own set of frequencies to be
rewarded and inhibited and this stayed the same for
each pair of sites for each individual patient.
Sessions commenced at the temporal locations (T3,
T4) for three to five sessions and then moved to central
areas (C3, C4), then frontal (F3, F4), prefrontal (FP1,
FP2), and parietal (P3, P4) for typically one to two ses-
sions at each location. Only these five pairs of sites were
used with the migraine protocols. We find that starting
at the temporal lobe locations seems to offer the most
powerful relaxation and stabilization initially in order
for us to be able to proceed to the other locations
which may not always be as relaxing or stabilizing. If
patients had an adverse reaction to any of these sites,
we moved on to another location. On rare occasions, a
patient would respond by becoming too activated by
work at a certain site so we would move to other sites
in the treatment regimen. A typical treatment regimen
would resemble the following: Sessions 1-4- EEG bio-
feedback at the temporal lobes simultaneously with ther-
mal handwarming biofeedback, session 5-9- EEG
biofeedback at central, frontal and parietal areas simul-
taneously with thermal handwarming biofeedback, Ses-
sion 10, 12, 14, 16, 18, 22, 26, 30, 34, 38- pIR HEG
biofeedback, Sessions 11,13, 15,17, 19-21, 23-25, 27-29,
31-33, 35-37, 39 & 40- EEG biofeedback at various loca-
tions along the cortex (depending on patient presenta-
tion and response) simultaneously with thermal
handwarming biofeedback. Although we do only one or
two sites per session, we have found the best responses
with migraineurs when we continue to move around the
whole head at various placements because we find that
this population can be easily irritated by the overtraining
of one site.
For most patients 30 minutes of pIR HEG biofeedback
was introduced at approximately their tenth visit. This
involved the patients wearing a headset which is
designed to be worn at FPZ (center of forehead) and
watching a movie and being challenged to keep the
movie playing as the reward threshold was re-set to
higher temperatures. The movie would remain playing
as long as the patient’s forehead temperature increased
as the threshold was re-set. After two sessions the fre-
quency-based neurofeedback training was reintroduced,
and generally conducted pIR HEG every 2
nd or 3
rd ses-
sion along with neurofeedback for the remainder of the
treatment period. Rationale for changing the order and
number of each of these protocols was based on patient
tolerance and effectiveness of each protocol and was
always subject to change based on patient feedback. We
have found that if we allow the patient to elevate their
forehead temperature more than 2 degrees, or if they
are worked too aggressively, it is more likely that this
technique can have the side effect of causing rather than
aborting a migraine. Therefore, patients were asked to
gently but mindfully increase their temperatures in
order to watch the movie and we did not challenge
them aggressively to do so by too frequently resetting
the reward threshold.
Thermal handwarming biofeedback was also used
simultaneously along with the EEG biofeedback during
clinic sessions. All patients were given thermal biofeed-
back units along with instructions for how to perform
thermal biofeedback at home on the days they did not
have a clinic session. An analysis of biofeedback in com-
bination with home training was found to be more
effective than therapies without home training [5]. The
objectives of this study are to show that the combina-
tion of both neurofeedback modalities along with ther-
mal biofeedback and medication will significantly lessen
the frequency of headaches experienced by the partici-
pants and that these effects will be more robust than
thermal biofeedback-only approaches and more effective
and enduring than traditional medication-only
approaches.
Instrumentation
Frequency-based EEG biofeedback protocols used the
Neurocybernetics (EEG Spectrum, International, Canoga
Park, CA) with Procomp amplifiers (Thought Technol-
ogy, Montreal, Quebec, Canada) or the Brainmaster sys-
tems (Brainmaster Technologies, Oakwood Village, OH).
Passive Infrared Hemoencephalography units were also
used (Jeffrey Carmen, Manlius, NY). Thermal hand-
warming biofeedback utilized the SC-911 unit (Biomedi-
cal Instruments, Inc., Warren, MI).
Results
Table 2 shows the age and gender of everyone in the
full sample and the pre-treatment and post-treatment
migraine frequency estimates. The estimates are based
on participant reports of the average number of
migraines they experienced per month in the 6 months
prior to treatment, and the 6 months immediately pre-
ceding the follow-up telephone survey. The small num-
ber of participants (n = 7) who had completed
treatment only 1 to 5 months before the follow-up
interview, reported migraine frequency for this shorter
post-treatment time period. The pre-treatment mean
frequency was 7.6 migraines per month (S.D = 5.1) the
post-treatment mean was 2.9 migraines per month (S.D
= 2.8), and the mean difference was 4.72 (S.D. = 4,32)
few migraines per month. The standardized effect size
(derived by dividing the mean difference score by the
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effect size considered in the literature to be very large.
S i n c em a n ym i g r a i n es t u d i e si n c l u d eo n l yt h o s ew h o
experience 2 to 14 migraines per month we also calcu-
lated effect size eliminating the 5 patients with 15 to 20
migraines/month and the 4 who experienced only one
per month. This produced and even larger effect size:
1.23. We next added in 3 “dummy” cases showing no
change to address concerns that those who fail to com-
plete the minimum number of sessions (the minimum
was 20, most had at least 40) might have been non-
responders. This effort to approximate an “ intention to
treat” analysis, assuming a 10% non-completer rate,
reduced the 1.23 effect size in the restricted , 2 to 14
migraine sample, to 1.00, still a very large effect size.
For each individual we also calculated the percent
reduction in migraine frequency by dividing the differ-
ence between that individual’s pre- and post-treatment
migraine frequency estimates by the average number of
pre-treatment migraines they experienced. As illustrated
in Figure 1, 70% of the sample (or 26/37) showed a 50%
or greater reduction in the frequency of their migraines,
and only 16% (or 6/37) failed to improve at all.
The significance of the observed changes was exam-
ined using the Wilcoxon signed ranks test, a non-para-
metric alternative to the t-test for small sample studies
where the dependent variable is not normally distribu-
ted. In the Wilcoxon signed ranks test the differences
between pre- and post-treatment scores are rank
ordered, and the significance test is based on ranks,
eliminating the potential biasing effects of large, spur-
ious differences in either direction. If the treatment has
no effect the sum of the ranks where the difference is
positive should be nearly equal to the sum of the ranks
where the difference is negative.
In the present case, there was a large difference; in 31
cases post-treatment scores (average number of
migraines per month) were less than pre-treatment
scores, in 6 cases scores were equivalent, and there were
no cases where post-treatment scores were greater than
pre-treatment scores. The resulting z-score of -4.86 was
statistically significant at the p < .001 level.
Although the focus of this study was on migraine
headaches, patients seeking neurotherapy are typically
experiencing more than one problem, and migraine
patients are no exception. In the follow-up interviews
we asked participants to (a) indicate which of several
other common symptoms they were experiencing when
t h e yf i r s ts o u g h tt r e a t m e n t , and then (b) use a 5-point
scale to rate the level of improvement they experienced
following neurotherapy treatment. The response scale
options were “no improvement” (0), “slight (10-30%)
improvement” (1), “moderate (40%-60%) improvement”
(2), “major (70-90%) improvement” (3), and “total (90-
100%) improvement” (4). Table 3 shows the number of
individuals rating the 6 most common symptoms
(migraine is included and the N of 34 indicates that we
did not get ratings from 3 of the migraineurs who pro-
vided headache frequency data), and the percent report-
ing three levels of improvement. The first group
includes those who selected either the “No improve-
ment” or the “Slight (10-30%) improvement” response
options, the middle group includes those who selected
the “Moderate (40-60%) response option, and the third
group includes those who selected “Major (70-90%) or
Total (100%) improvement. Migraines were the most
improved symptom based on this scale, with 62% or 23/
37 reporting major or total improvement, followed by
“other headaches,” where 50% or 19/37 reported major
or total improvement. The percent reporting major or
total improvement on other symptoms ranged from 32%
to 41%. Sleep problems were least likely to be substan-
tially improved.
Discussion
The concept of an under or overaroused nervous system
was first proposed by Nobel Laureate Walter Rudolph
Hess who in the 1950s experimented with electrical sti-
mulation of the brain which led to changes in arousal
[26]. It has been theorized that disorders of attention,
affect and pain are due either to over or underaroused
brain states, and that neurofeedback is effective for a
variety of symptoms or symptom clusters because it
improves the brain’s ability to regulate these arousal
states [13]. Neurofeedback treatment protocols address
the underlying arousal problem, obviating separate vali-
dation studies for every medical diagnosis [13]. In this
study, it appears that the biofeedback enabled the
patients to gradually learn to control their susceptibility
to getting headaches. Generally, they began to notice
gradual improvements early on in treatment, particularly
in their ability to manage stress, which was impetus for
continuing treatment. This was assessed every 10 ses-
sions by a written checklist and by interviews with a
psychologist at each session. By session 20, most began
to be aware of their ability to control or prevent their
headaches. In most cases, by session 40, patients felt a
sense of increased mastery over being better able to
recognize when they were at risk (increased autonomic
arousal in reaction to stress) and to take appropriate
measures to be able to prevent headaches. 40 sessions
happened to be the average number of sessions underta-
ken in the study. Number of sessions ranged from 20-67
and was determined by what treatment provider and
each patient felt they needed in order to ultimately learn
to control migraines. These patients described the bio-
feedback as helping them to acquire the ability to better
self-regulate by learning to control their EEG and
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breathing and warming their hands and forehead, all of
which were necessary for the types of biofeedback they
had undergone. When asked how they thought they
were better able to prevent headaches during interviews
at each session and on checklists after every 10 sessions,
many would explain that during potentially stressful
conditions they would imagine hearing or visualizing the
neurofeedback games and this appeared to help them
invoke the physiological state elicited during the actual
sessions. We have observed that thermal biofeedback
devices (pIR HEG machine and the handwarming units)
can often be powerful migraine abortives once patients
learn to raise their hand or forehead temperatures. All
clients, whether or not they were successful at reducing
their migraines, demonstrated an ability to warm their
hands and foreheads and decrease their elevated EEG
amplitudes of both slow and fast-wave activity. Patients
related during session interviews that these techniques
have eventually enabled them to automatically learn to
abort their headaches without having to use the actual
devices. Of the 37 patients in the study, five had fifteen
Table 2 Sample characteristics and average number of migraines per month pre- and post-treatment
Age Gender Average # of migraines/mo pre-treatment Average # of migraines/mo post-treatment Difference
40 f 1 0 1
41 m 1 0 1
9 m 1 0.16 0.84
15 f 1 0 0.7
50 f 2 0.5 1.5
39 f 2 2 0
20 m 2 0.3 1.7
42 f 3 3 0
62 f 3 0 3
9m 3 1 2
52 f 4 4 0
57 f 4 0 4
13 f 4 0.5 3.5
14 f 5 3 2
27 m 6 6 0
10 f 6 4 2
33 f 6 1 5
47 f 7 5.5 1.5
21 f 8 0.5 7.5
69 f 8 8 0
18 f 8 2 6
25 f 8 0 8
38 f 9 0 9
58 f 10 4 6
16 f 10 10 0
49 f 10 2 8
44 f 10 3 7
45 f 10 1 9
48 m 10 6 4
79 f 10 4 6
55 f 13 10 3
15 m 14 5 9
55 f 15 4 11
59 f 15 5 10
15 f 15 3 12.5
20 f 18 2 16
47 m 20 7 13
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Page 7 of 10or more migraines a month and all five improved signif-
icantly which may show promise that these methods can
be useful for preventing the progression from episodic
to chronic migraine.
Central nervous system dysfunction may play a key
role in the pathogenesis of migraine [16-21]. As there
are no apparent structural disturbances, clinical neuro-
physiological methods may be well-suited to study its
pathophysiology [16]. In both migraine with and without
aura, somatosensory evoked potential studies show that
lack of habituation in cortical information processing
between attacks is a reproducible central nervous system
abnormality with this population [19]. Siniatchkin et al
demonstrated the vulnerability of the migraine brain by
measuring the effects of experimentally-induced stress
on the contingent negative variation (CNV) response,
which is a slow cortical potential believed to reflect
altered excitability. This study showed a susceptibility to
stress-induced migraine provoking agents before an
actual attack [20]. Additionally, it has been observed
that abnormal behavioral patterns such as hypersensitiv-
ity and perfectionism are often characteristic among
migraine sufferers yet these psychological features may
be the result of an innate cortical hypersensitivity in
addition to associated social learning processes [21]. In
this study neurofeedback appears to have improved
stress resilience and susceptibility to migraines in the
migraine participants. This may be due to the increase
in self regulation brought about by the process of long
term potentiation that may result from the operant con-
ditioning of the EEG during the neurofeedback training
[12].
Migraine has a comorbid association with a number of
psychiatric conditions, including bipolar disorder, anxi-
ety states, and depression, all of which are associated
with perturbations in the serotonin and norepinephrine
neurotransmitter substances [27,28]. Depression is often
comorbid with migraines and anti-depressants are often
used to treat both conditions [29]. Evidence that many
neurological conditions are comorbid and alleviated by
identical or very similar drugs supports three important
principles in the spectrum paradigm: a) different symp-
toms are often manifestations of the same underlying
instability or in balance, b) symptoms manifest differ-
ently depending on where they fall along the continuum
of the underlying dysfunction, c) treatments need not be
“disease specific” to be helpful [13]. Neurologist Oliver
Sacks’ speculation that brainwave biofeedback might
prove useful for migraines after showing promise in
treating seizures supports the spectrum concept of
related disorders responding to one mode of treatment
[30].
Migraine and tension type headache were linked after
both types showed a significant response to sumatriptan.
A convergence hypothesis was proposed speculating that
the entire clinical spectrum of headache may share a
common physiological pathway based on one type of
medication exerting an effect on two distinctly different
types of headache [31,32]. Similarly, an older study
shows that neurofeedback was effective for tension type
headache [11] and our study finds that several types of
biofeedback have an effect on migraines, other types of
headache and other comorbidities.
Biofeedback used with medications appears to outper-
form medications alone [5,33,34]. In our study involving
biofeedback with clients using medications, we saw the
f r e q u e n c yo fu s a g eo ft h ea b o r t i v ea n dr e s c u em e d i c a -
tions drop along with the frequency of headaches.
Limitations
This study did not focus solely on neurofeedback as a
stand-alone treatment. The simultaneous inclusion of
Figure 1 Percent of total sample who experienced levels of
improvement in migraine frequency.
Table 3 Ratings of improvement on migraine and other presenting problems
Number giving ratings Slight or no improvement Moderate improvement Major or total improvement
Migraine headaches 34 21% 18% 62%
Anxiety 31 32% 36% 32%
Focus 29 35% 28% 38%
Other headaches 28 25% 25% 50%
Depression 27 33% 26% 41%
Sleep 22 46% 23% 32%
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known to be effective for migraines confounds this
study. The study design is not ideal in that it prevents
any supposition as to which interventions may be at
work in cases of improved headaches. Because the study
was unblinded and the treatment protocol was modified
according to individual patient reactions, it does not
meet the standards for a clinical trial. A single group
(non-random) retrospective review of a convenience
sample of headache sufferers without a control group
and interviewed as long as 24 months after treatment
with a varying treatment protocol is perhaps reflective
of clinical practice but not ideal for investigating a novel
approach to managing headaches. Additionally, the
response scales used to construct Table 3 did not
include the choice of “worse”, which may have induced
an overly acquiescent response bias. The simultaneous
measuring of pre and follow-up data is problematic also,
since it may introduce several potential biases such as
memory and recency effects.
Great care was also taken to rule out positive biases
that might have been introduced by having data collected
by people the patients had known or seen at the clinic.
Those conducting the telephone survey made an effort to
assure respondents that this was an objective effort to
learn about both positive and negative outcomes. Never-
theless, retrospective reports of migraine frequency are
not ideal. If we were paying subjects to participate in an
externally funded study, we could require participants to
complete daily headache diaries for several months post-
treatment. This is not practical in practice-based
research, however, especially when treatment has effec-
tively reduced the frequency or severity migraines to the
point that they are no longer a focus of concern.
Conclusions
M i g r a i n em a yb ep r o g r e s s i v edisorder with an excellent
response to preventive early interventions [33,34]. Yet
none of the pharmaceutical options are exceptionally
effective or without side effects. The best result that
medication has achieved has been only about a 50%
reduction in approximately 50% of migraine patients
[34]. Our study outperforms this by achieving a 50% or
more reduction in 70% of the participants based on fol-
low-up data collected on average, 14 months after
patients had completed at least the minimum recom-
mended 20 treatment sessions. The treatment effect
sizes we obtained (1.09) are greater than those reported
in a recent meta-analysis for either EEG-biofeedback
(about .4) or temperature training feedback (about .5) or
blood volume pulse feedback (about .7) alone, or tem-
perature feedback plus electromyographic feedback
(about .6) [5]. Although we did not have a control
group, and thus cannot completely rule out placebo
effects in this study, it may be unusual for a placebo
effect to last 6 months to two years.
Despite the different types of intervention used in our
study (manipulation of the EEG, forehead temperature or
hand temperature), the retrospective reports of migraine
frequency and the absence of a control group, the statisti-
cally and clinically significant improvements observed in
this patient population attests to the promise biofeedback
based treatment modalities hold for migraine patients. It
is our hope that this study will generate an interest in
performing larger scale controlled studies in the non-
invasive neurotherapies to treat migraine and other
chronic and/or progressive disorders.
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